Scientists at the University of East Anglia have shown how the main psychoactive ingredient in cannabis could reduce tumor growth in cancer patients.
Research published in the Journal of Biological Chemistry reveals the existence of previously unknown signaling platforms which are responsible for the drug’s success in shrinking tumors. It is hoped that the findings could help develop a synthetic equivalent with anti-cancer properties.
The research was co-led with the Universidad Complutense de Madrid in Spain.
The team used samples of human cancer cells to induce tumors in mice. They then targeted the tumors with doses of the cannabis compound THC (Tetrahydrocannabinol). They found that two cell receptors in particular were responsible for the drug’s anti-tumor effects.
Dr. Peter McCormick, from UEA’s School of Pharmacy, said: “THC, the major active component of marijuana, has anti-cancer properties. This compound is known to act through a specific family of cell receptors called cannabinoid receptors. However, it was unclear which of these receptors were responsible for the anti-tumor effects of THC.
“We show that these effects are mediated via the joint interaction of CB2 and GPR55 – two members of the cannabinoid receptor family. Our findings help explain some of the well-known but still poorly understood effects of THC at low and high doses on tumor growth.
McCormick added: “By identifying the receptors involved we have provided an important step towards the future development of therapeutics that can take advantage of the interactions we have discovered to reduce tumor growth.”
McCormick emphasized that cancer sufferers should not be tempted to self-medicate. “Our research uses an isolated chemical compound and using the correct concentration is vital. Cancer patients should not use cannabis to self-medicate, but I hope that our research will lead to a safe synthetic equivalent being available in the future.”
Journal of Biological Chemistry, July 14, 2014
University of East Anglia (http://www.uea.ac.uk)